Live Breaking News & Updates on Halsin Partners|Page 7

Stay updated with breaking news from Halsin partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia .
Addex TherapeuticsJune 29, 2021 GMT
Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID). Dyskinesia is believed to be caused by increased glutamatergic neurotransmission. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5, or mGlu5 to downregulate this neurotransmission through allosteric modulation. ....

United States , Tim Dyer , Mike Sinclair , Movement Disorders , Janssen Pharmaceuticals , Addex Therapeutics Ltd , Janssen Pharmaceuticals Inc , Swiss Exchange , Therapeutics Ltd , Unified Dyskinesia Rating Scale , Global Impression , Chief Executive Officer , New England Journal , American Depositary Shares , Halsin Partners , ஒன்றுபட்டது மாநிலங்களில் , நேரம் சாய தொழிலாளி , மைக் சின்க்ளேர் , இயக்கம் கோளாறுகள் , ஜான்சன் மருந்துகள் , ஜான்சன் மருந்துகள் இன்க் , சுவிஸ் பரிமாற்றம் , சிகிச்சை லிமிடெட் , உலகளாவிய எண்ணம் , தலைமை நிர்வாகி அதிகாரி , புதியது இங்கிலாந்து இதழ் ,

Press Release: Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

First patients enrolled into multi-center U.S. study

Geneva, Switzerland, June 7, 2021 Addex Therapeutics. | June 7, 2021 ....

United States , Tim Dyer , Company Annual Report On Form , Janssen Pharmaceuticals Inc , Swiss Exchange , Janssen Pharmaceutical Companies Of Johnson , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies , About Addex Therapeutics , Addex Therapeutics , American Depositary Shares , Mike Sinclair , James Carbonara , Chief Executive Officer , Halsin Partners , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Addex Therapeutic , Dow Jones , Addex Therapeutics Ltd Stock Exchange , Press Release , Ddex Adxn Ch0029850754 , ஒன்றுபட்டது மாநிலங்களில் , நேரம் சாய தொழிலாளி , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் ,

Press Release : Addex to Participate at the Benchmark Company Healthcare House Call Conference

Message :
Required fields
Geneva, Switzerland, May 24, 2021 Addex Th
https://www.globenewswire.com/Tracker?data=GKEDSALQ3NE4EtVCK9RzLXOk8Q1WB4CkSAscPRzRqf0SdKsQfRwX9gF3D5OianoM6yqhedJ0aWDLbl85uBW8pGIBsUsozfgyWuKSHEalz5Y=
e
https://www.globenewswire.com/Tracker?data= w0gykO1cRWXvNInzg 3desjb1 u59TFS0A9iWd0zSqOojFGKcGUUTA-pVC88i-7tgLyk1ZFhlOA qCsbfnT9w==
rapeutics
https://www.globenewswire.com/Tracker?data=Hs rkfRwMjZ7W-Q8M7njxKHxgbDMLkKODX R98HbsH48L3DiAk0zV907yb2MqLBez4xLV5rL mMX9NC-yZhLsWbD6D6sL4p11kl1LT-ApNA=
(SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company
pioneering allosteric modulation-based drug discovery and development,
announced today that Tim Dyer, Chief Executive Officer, will participate ....

United States , Tim Dyer , Company Annual Report On Form , Company Healthcare House Call Conference On , Janssen Pharmaceuticals Inc , Swiss Exchange , Chief Executive Officer , About Addex Therapeutics , Addex Therapeutics , Janssen Pharmaceuticals , American Depositary Shares , Mike Sinclair , James Carbonara , Halsin Partners , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Addex Therapeutic , Dow Jones , Addex Therapeutics Ltd Stock Exchange , Press Release , Ddex Adxn Ch0029850754 , ஒன்றுபட்டது மாநிலங்களில் , நேரம் சாய தொழிலாளி , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , ஜான்சன் மருந்துகள் இன்க் ,

Addex Increases Issued Share Capital to Create Treasury Shares

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex Increases Issued Share Capital to Create Treasury Shares
Addex TherapeuticsApril 26, 2021 GMT
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its share capital from 39,748,635 to 49,272,952 through the issue of 9,524,317 new registered shares at a nominal value of CHF1 each to Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s authorized capital, are listed on the SIX Swiss Exchange. The transaction has been executed to provide the Group with additional future financing flexibility. ....

United States , Addex Pharma , Tim Dyer , Mike Sinclair , Company Annual Report On Form , Addex Therapeutics Ltd , Janssen Pharmaceuticals Inc , Swiss Exchange , Therapeutics Ltd , Addex Therapeutics , Janssen Pharmaceuticals , American Depositary Shares , Halsin Partners , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Globe Newswire , ஒன்றுபட்டது மாநிலங்களில் , நேரம் சாய தொழிலாளி , மைக் சின்க்ளேர் , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , ஜான்சன் மருந்துகள் இன்க் , சுவிஸ் பரிமாற்றம் , சிகிச்சை லிமிடெட் , ஜான்சன் மருந்துகள் , பார்க்கிறது அறிக்கைகள் ,

Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum
Addex TherapeuticsApril 26, 2021 GMT
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 4ᵗʰ Annual Neuroscience Innovation Forum (April 26 - 30, 2021).
In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing to registered participants at the forum. Mr Dyer will also be speaking at the Parkinson’s & Movement Disorders Panel scheduled for 13:20 EDT, April 28, 2021. ....

Tim Dyer , Mike Sinclair , Company Annual Report On Form , Parkinson Movement Disorders Panel , Neuroscience Innovation Forum , Addex Therapeutics Ltd , Janssen Pharmaceuticals Inc , Swiss Exchange , Therapeutics Ltd , Chief Executive Officer , Annual Neuroscience Innovation Forum , Movement Disorders Panel , Addex Therapeutics , Janssen Pharmaceuticals , Halsin Partners , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Globe Newswire , நேரம் சாய தொழிலாளி , மைக் சின்க்ளேர் , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , நரம்பியல் கண்டுபிடிப்பு மன்றம் , ஜான்சன் மருந்துகள் இன்க் , சுவிஸ் பரிமாற்றம் , சிகிச்சை லிமிடெட் ,